- ISIN
- US45258H1068
- CUSIP
- 45258H106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 16, 2021
Highlights
- Market Cap
- $452.62M
- Enterprise Value
- $374.54M
- EPS (TTM)
- -$0.84
- Gross Profit (TTM)
- -$90.63K
- EBITDA (TTM)
- -$35.73M
- Year Range
- $1.94 - $12.14
- Target Price
- $14.50
- ROA (TTM)
- -36.51%
- ROE (TTM)
- -41.47%
- Avg. Volume (1M)
- 2M
- Avg. Volume Value (1M)
- $18.10M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
IMMX Performance Chart
Immix Biopharma, Inc. (IMMX) is up 59.1% since the beginning of the year. At $8 per share, IMMX is trading 31.5% below its 52-week high of $12.
Loading charts...
Compare this symbol against anything
Returns By Period
Immix Biopharma, Inc. (IMMX) has returned 59.08% so far this year and 213.96% over the past 12 months.
Immix Biopharma, Inc.
- 1D
- -2.69%
- 1M
- -19.54%
- 6M
- 42.71%
- YTD
- 59.08%
- 1Y
- 213.96%
- 3Y*
- 59.51%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 11.65%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
IMMX Monthly Returns History
Based on dividend-adjusted daily data since Dec 16, 2021, IMMX's average daily return is +0.27%, while the average monthly return is +4.56%. At this rate, an investment would double in approximately 1.3 years.
Historically, 50% of months were positive and 50% were negative. The best month was Dec 2022 with a return of +89.3%, while the worst month was Jan 2024 at -44.8%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.
On a daily basis, IMMX closed higher 46% of trading days. The best single day was Jan 3, 2022 with a return of +62.4%, while the worst single day was Dec 16, 2021 at -26.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 11.47% | 38.42% | 12.89% | -1.98% | 0.78% | 14.56% | -19.30% | 59.08% | |||||
| 2025 | -11.82% | -8.25% | -5.62% | 25.60% | 10.90% | -11.54% | 31.40% | -18.38% | -5.86% | 81.82% | 11.84% | 23.06% | 137.73% |
| 2024 | -44.80% | -12.30% | -8.36% | -29.32% | -2.76% | -6.16% | 4.55% | 3.38% | -30.37% | 7.38% | 31.88% | 4.27% | -68.21% |
| 2023 | 13.54% | -20.00% | -12.50% | 35.71% | -18.22% | 33.17% | -23.42% | -1.46% | 68.47% | 5.85% | 41.16% | 35.42% | 202.18% |
| 2022 | 14.04% | -26.60% | -19.13% | -42.74% | 55.07% | 21.50% | -6.15% | -25.41% | -25.27% | -26.47% | 21.00% | 89.26% | -35.67% |
| 2021 | -28.80% | -28.80% |
Benchmark Metrics
Immix Biopharma, Inc. has an annualized alpha of 73.62%, beta of 1.11, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since December 16, 2021.
- This stock captured 14.83% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -45.67%) - a profile typical of hedging or uncorrelated assets.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 73.62%
- Beta
- 1.11
- R²
- 0.03
- Upside Capture
- 14.83%
- Downside Capture
- -45.67%
Return for Risk
Risk / Return Rank
IMMX ranks 92 for risk / return — above 92% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Immix Biopharma, Inc. (IMMX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| IMMX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.98 | ||
| Sortino ratioReturn per unit of downside risk | +0.90 | ||
| Omega ratioGain probability vs. loss probability | 1.33 | 1.25 | +0.08 |
| Calmar ratioReturn relative to maximum drawdown | 5.20 | 2.00 | +3.20 |
| Martin ratioReturn relative to average drawdown | 11.08 | 8.49 | +2.58 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Immix Biopharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Immix Biopharma, Inc. was 88.89%, occurring on Nov 10, 2022. Recovery took 275 trading sessions.
The current Immix Biopharma, Inc. drawdown is 30.78%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-88.89%Nov 2022 | 10mo 8d | 1y 1mo | 1y 11moJan 2022 - Dec 2023 | Bear market2022 |
-81.57%Oct 2024 | 9mo 20d | 1y 2mo | 1y 11moDec 2023 - Dec 2025 | — |
-41.00%Dec 2021 | 7d | 11d | 18dDec 2021 - Jan 2022 | — |
-39.84%Jan 2026 | 1mo 1d | 1mo 1d | 2mo 2dDec 2025 - Feb 2026 | — |
-32.03%Jul 2026 | 21d | — | 26dJul 2026 - now | — |
Drawdown Indicators
| IMMX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -88.89% | -56.78% | -32.11% |
Max Drawdown (1Y)Largest decline over 1 year | -39.84% | -9.10% | -30.74% |
Max Drawdown (3Y)Largest decline over 3 years | -81.57% | -18.90% | -62.67% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -30.78% | -1.58% | -29.20% |
Average DrawdownAverage peak-to-trough decline | -57.44% | -10.70% | -46.74% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.68% | 2.14% | +16.54% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Immix Biopharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Immix Biopharma, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for IMMX in comparison with other companies in the Biotechnology industry. Currently, IMMX has a P/B value of 5.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with IMMX
Add Immix Biopharma, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with IMMX